// App-Quantinova.ai

163 : A multi-centre retrospective study to describe the real world effectiveness of golimumab for treating ankylosing spondylitis (AS) in UK clinical practice

Researchers

Presenter

  • Karl Gaffney

Principal Investigators

  • Lisa Dunkley

  • Nicola Goodson

  • Sean Kerrigan

  • David Marshall

  • Ognjenka Savanovic-Abel

  • Raj Sengupta

  • Christine A Mackay

  • Eleana Tsoumani

  • Catherine Bottomley

  • Tim Futter

  • Joseph Hickey

Medical Centers

  • Rheumatology, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, UNITED KINGDOM

  • Physiotherapy, Sheffield Teaching Hospitals, Sheffield, UNITED KINGDOM

  • Rheumatology, Aintree University Hospital, Liverpool, UNITED KINGDOM

  • Rheumatology, Greater Glasgow & Clyde NHS Trust, Glasgow, UNITED KINGDOM

  • Rheumatology, Inverclyde Royal Hospital, Greenock, UNITED KINGDOM

  • Rheumatology, Derriford Hospital, Plymouth, UNITED KINGDOM

  • Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom

  • Medical Affairs, MSD, Hoddesdon, UNITED KINGDOM

  • Research, pH Associates (an Open Health company), Marlow, UNITED KINGDOM

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Autoimmune (AI)

Disease

  • Ankylosing spondylitis

Biomarkers

  • N/A

Drug/Treatment

  • golimumab

Outcome

  • N/A

Study Design

  • Observational

  • Multicenteric

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Merck Sharp & Dohme (MSD)

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved